COR
$326.91-4.83 (-1.46%)
Cencora, Inc.
Recent News
Here’s Why Cencora (COR) Shares Rose 8% in Q4
TimesSquare Capital Management, an equity investment management company, released its “U.S. Focus Growth Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The strategy returned -3.55% (gross) and -3.76% (net) in the fourth quarter compared to a -3.70% return for the Russell Midcap Growth Index. In 2025, the strategy returned 14.84% […]
1 Healthcare Stock with Exciting Potential and 2 We Ignore
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 3.6% over the past six months, topping the S&P 500 by 2.3 percentage points.
Here's Why You Should Hold Cencora Stock in Your Portfolio for Now
Cencora's strong U.S. growth, MSO strategy, and raised outlook support long-term potential, but competition and customer losses remain key risks.
Cencora CFO announces retirement
James Cleary will step down from the post on June 30, but stay on as an adviser to the company through the end of the year. He’s the second finance chief of a drug distributor to announce their retirement this month.
How Cardinal Health, The IBD Stock Of The Day, Is Navigating The Tricky Macro
Cardinal Health is Friday's IBD Stock Of The Day. Shares are in a buy zone as the medical wholesaler easily navigates macro challenges.